Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease [Phase 3]

View source ↗

Summary

Roche's Phase 3 trial is evaluating intravenous prasinezumab for early-stage Parkinson's disease and is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• prasinezumab (prasinezumab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Parkinson's Disease | Phase 3 | Status: RECRUITING